PTCT Stock Analysis: Buy, Sell, or Hold?
PTCT - PTC Therapeutics, Inc.
$72.72
-0.74 (-1.01%)
▼
5d:
+12.76%
30d:
-1.16%
90d:
+2.86%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When PTCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PTCT shows positive signals but monitor for confirmation. Market pricing in 1.3% decline. Moderate conviction.
💡 BUY OPPORTUNITY: PTCT shows positive signals but monitor for confirmation. Market pricing in 1.3% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$135.50
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$84.14
13.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PTCT is currently trading at $72.72, which is considered extended relative to its 30-day fair value range of $66.40 to $73.03. The stock's valuation (Forward PE: 26.1) is in line with its historical norms (27.2). Remarkably, the market is currently pricing in an annual earnings decline of 1.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PTCT is in a strong downtrend. Immediate support is located at $63.18, while resistance sits at $79.91.
Market Sentiment: PTCT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $90.60 (+24.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PTCT is in a strong downtrend. Immediate support is located at $63.18, while resistance sits at $79.91.
Market Sentiment: PTCT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $90.60 (+24.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$66.40 -
$73.03
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 24.6% below Wall St target ($90.60)
Trading Range Analysis
30-Day Trading Range
$66.40 -
$73.03
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$63.18
Resistance Level
$79.91
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
26.13
Wall Street Target
$90.60
(+24.6%)
Revenue Growth (YoY)
-76.8%
Profit Margin
-22.6%
Valuation Discount vs History
-1.3% cheaper
PE vs Historical
26.1 vs 27.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.3%
(market-implied from PE analysis)
1-Year Target
$71.77
(-1%)
2-Year Target
$70.84
(-3%)
3-Year Target
$69.92
(-4%)
3-Yr Target (if PE normalizes)
(PE: 26→27)
$72.79
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.1, Growth: 111.9%)
$245.43
(+238%)
Base:
(SPY PE: 22.0, Growth: 111.9%)
$207.04
(+185%)
Bear:
(PE: 18.7, Growth: 111.9%)
$175.98
(+142%)
📈
Valuation based on Current Earnings
Trailing PE: 7.52 | Current EPS (TTM): $8.58
Bull Case
$35.47
(-52%)
Analyst growth -50.0%, PE expands to 8.3
Base Case
$32.24
(-56%)
Market implied -50.0%, PE stable at 7.5
Bear Case
$43.85
(-41%)
Severe decline -20.0%, PE contracts to 6.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 26.1 to 27.2
Stabilization Target:
$75.71
(+4.1%)
PE Expansion Potential:
+4.1%
Share & Embed Analysis
Last updated: May 15, 2026 5:27 AM ET
Data refreshes hourly during market hours. Next update: 6:27 AM
Data refreshes hourly during market hours. Next update: 6:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Matthew B Klein
SELL
2850 shares
2026-04-21
Mark Elliott Boulding
SELL
2265 shares
2026-04-06
Lee Scott Golden
SELL
829 shares
2026-04-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 62 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 64 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 60 BUY |
